摘要
近年来2型糖尿病(T2DM)患者恶性肿瘤的发病率明显增加。二甲双胍作为T2DM的一线口服药物,除了安全有效的降糖作用,还能减少T2DM患者多种癌症的发生和死亡风险,并可以改善预后。其具体机制尚未明确,可能主要是通过作用于一磷酸腺苷活化蛋白激酶(AMPK)和微小RNA(miRNAs)来抑制肿瘤细胞的增殖和促进其凋亡,并通过抑制肿瘤细胞迁移和侵袭、协同化疗药物治疗等发挥抗癌作用。本文对近年来针对二甲双胍与癌症治疗的研究及可能的抗癌机制作一综述。
The incidence of malignancy tumors has increased significantly recent years in patients with type2diabetes mellitus(T2DM).As the first-line oral medicine of T2DM,in addition to the safe and effective hypoglycemic effect,metformin can reduce the incidence and mortality of cancer,and improve the prognosis in T2DM patients.While the exactly anti-tumor mechanisms of metformin is not yet clear,which might be the inhibition of proliferation and promotion of apoptosis of tumor cells mainly by acting on an adenosine monophosphate activated protein kinase(AMPK)and microRNAs(miRNAs).And metformin can inhibit migration and invasion of tumor cells,as well as strengthen the effects of chemotherapy drugs.This article reviews the recent research progress of clinical and epidemiological studies and anticancer mechanisms of metformin.
作者
周侠
缪珩
ZHOU Xia;MIAO Heng(Department of Endocrinology, the Second Affiliated Hospital of Nanjing Medical University,Nanjing 210000, China)
出处
《天津医药》
CAS
2017年第7期767-771,共5页
Tianjin Medical Journal
关键词
二甲双胍
肿瘤
糖尿病
2型
细胞增殖
细胞凋亡
微RNAS
综述
一磷酸腺苷活化蛋白激酶
metformin
neoplasms
diabetes mellitus, type 2
cell proliferation
apoptosis
microRNAs
rewiew
adenosine monophosphate activated protein kinase
